SNCA
ENSG00000145335
Target class
Unclassified protein
Chromosome
4
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- SNCA
- Gene name
- Synuclein alpha
- Gene symbol
- SNCA
- Protein name
- Alpha-synuclein (Non-A beta component of AD amyloid) (Non-A4 component of amyloid precursor) (NACP)
- NACP
- PD1
- PARK1
- PARK4
- Gene biotype
- Protein coding
- Gene family
- Synuclein family
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 48
- Highest tissue expression
- 106.1
- Tissue specificity (Gini)
- 0.653
- Tissue specificity (tau)
- 0.846
- KEGG gene identifiers
- hsa:6622
- Protein interaction confidence
- 0.844336
- Protein interaction partners
- 119
- R-HSA-977225
- R-HSA-9833482
- End position
- 89838315
- Start position
- 89700345
- Chromosome
- 4
- Strand
- Reverse
- Cytoplasm . Membrane . Nucleus . Synapse . Secreted . Cell projection, axon . Note=Membrane-bound in dopaminergic neurons (PubMed:15282274). Expressed and colocalized with SEPTIN4 in dopaminergic axon terminals, especially at the varicosities (By similarity). .
- PubMed 19762560
- PubMed 24936070
- PubMed 25561023
- PubMed 26442590
- PubMed 31034892
- PubMed 33657088
- PubMed 12859192
- PubMed 15282274
- Tissue specificity (tau)
- 0.846138
- Expression inequality (Gini)
- 0.653461
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 106.1
- Brain - Frontal Cortex (BA9)
- 105.95
- Brain - Anterior cingulate cortex (BA24)
- 75.04
- Brain - Cerebellum
- 73.93
- Nerve - Tibial
- 67
Expression in transcripts per million
- Brain - Cerebellar Hemisphere106.1
- Brain - Frontal Cortex (BA9)105.95
- Brain - Anterior cingulate cortex (BA24)75.04
- Brain - Cerebellum73.93
- Nerve - Tibial67
- Brain - Cortex58.82
- Brain - Spinal cord (cervical c-1)42.6
- Brain - Amygdala38.25
- Brain - Nucleus accumbens (basal ganglia)34.51
- Brain - Substantia nigra34.12
- Whole Blood33.48
- Brain - Hypothalamus32.29
- Brain - Hippocampus30.33
- Brain - Caudate (basal ganglia)23.66
- Uterus21.09
- Brain - Putamen (basal ganglia)19.75
- Ovary13.68
- Pituitary13.09
- Cervix - Endocervix12.09
- Cervix - Ectocervix11.64
- Colon - Sigmoid11.43
- Vagina10.14
- Prostate7.36
- Lung7.01
- Esophagus - Gastroesophageal Junction6.91
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0001774
- GO:0001921
- GO:0006749
- GO:0010040
- GO:0010642
- GO:0014059
- GO:0016079
- GO:0016082
- GO:0031115
- GO:0031623
- GO:0031648
- GO:0032026
- GO:0032496
- GO:0034341
- GO:0034599
- GO:0035493
- GO:0035543
- GO:0042416
- GO:0043065
- GO:0043066
- GO:0045807
- GO:0045920
- GO:0045921
- GO:0050729
And 22 more, listed on the interactive page.
- GO:0005576
- GO:0005634
- GO:0005737
- GO:0005739
- GO:0005764
- GO:0005829
- GO:0005886
- GO:0005938
- GO:0015629
- GO:0016020
- GO:0016234
- GO:0030424
- GO:0030426
- GO:0031092
- GO:0032991
- GO:0045202
- GO:0048471
- GO:0097413
- GO:0099512
- GO:0000149
- GO:0000287
- GO:0000976
- GO:0003779
- GO:0004857
- GO:0004860
- GO:0004869
- GO:0005504
- GO:0005507
- GO:0005509
- GO:0005515
- GO:0005543
- GO:0008047
- GO:0008198
- GO:0008270
- GO:0008289
- GO:0015631
- GO:0016491
- GO:0019894
- GO:0019899
- GO:0030544
- GO:0042393
- GO:0042802
- GO:0043014
- GO:0048156
And 6 more, listed on the interactive page.
Related records
Trials (9)
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease
- A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
- A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
- Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
- Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
- Prevent Cognitive Decline in GBA-associated Parkinson's Disease
- Single Ascending Dose Study of PRX002 in Healthy Subjects
- Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
Drugs (2)
- Cinpanemab Alpha-synuclein inhibitor
- Prasinezumab Alpha-synuclein binding agent